Rethinking dual disorders/pathology

Addictive Disorders and their Treatment

Volumn 12, Issue 1, 2013, Pages 1-10

  Szerman, Nestor ^a   Martinez Raga, Jose ^a,b,c   Peris, Lola ^a,d   Roncero, Carlos ^a,e,f   Basurte, Ignacio ^a   Vega, Pablo ^g   Ruiz, Pedro ^h   Casas, Miguel ^a,e,f  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d University of Valencia ^*  (Switzerland)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g Instituto de Adicciones   (Spain)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

addiction; dual disorders pathology; neurobiology; psychiatric comorbidity; substance use disorders

Indexed keywords

ADDICTION; ARTICLE; COMORBIDITY; DEGENERATIVE DISEASE; DEVELOPMENTAL DISORDER; DSM-IV; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; MENTAL DISEASE; NEURODEVELOPMENTAL DISORDER; PERSONALITY DISORDER; PRIORITY JOURNAL;

EID: 84874431131     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/ADT.0b013e31826e7b6a     Document Type: Article

References (63)

1. Adamson SJ, Todd FC, Sellman JD, et al. Co-existing psychiatric disorders in a New Zealand outpatients alcohol and other drug clinical population. Aust N Z J Psychiatry. 2006;40:164-170. (Pubitemid 43379410)
2. Hasin D, Fenton MC, Skodol A, et al. Personality disorders and the 3-year course of alcohol, drug, and nicotine use disorders. Arch Gen Psychiatry. 2011;68:1158-1167.
3. Swendsen J, Ben-Zeev D, Granholm E. Real time electronic ambulatory monitoring of substance use and symptom expression in schizophrenia. Am J Psychiatry. 2011;168:202-209.
4. Szerman N, Lopez-Castroman J, Arias F, et al. Dual diagnosis and suicide risk in a Spanish outpatient sample. Subst Use Misuse. 2012;47:383-389.
5. Volkow N. Drug abuse and mental illness: progress in understanding comorbidity. Am J Psychiatry. 2001;158:1181-1183. (Pubitemid 32717687)
6. Banerjee S, Clancy C, Crome I. Co-existing Problems of Mental Disorder and Substance Misuse (Dual Diagnosis): An Information Manual. London: Royal College of Psychiatrists Research Unit; 2002.
7. O'Brien G. Dual diagnosis in offenders with intellectual disability: setting research priorities: a review of research findings concerning psychiatric disorder (excluding personality disorder) among offenders with intellectual disability. J Intellect Disabil Res. 2002;46:(suppl 1):21-30. (Pubitemid 34546883)
8. Newton-Howes G, Tyrer P, Anagnostakis K, et al. The prevalence of personality disorder, its comorbidity with mental state disorders, and its clinical significance in community mental health teams. Soc Psychiatry Psychiatr Epidemiol. 2010;45:453-460.
9. Fagan PJ, Schmidt CW Jr, Wise TN, et al. Sexual dysfunction and dual psychiatric diagnoses. Compr Psychiatry. 1988;29:278-284.
10. Casas M. Trastornos duales. In: Vallejo Ruiloba J, Gastó Ferrer C, eds. Trastornos Afectivos: Ansiedad y Depression. 2nd ed. Barcelona: Masson. 2000; 890-899.
11. Weaver T, Madden P, Charles V, et al. Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. Br J Psychiatry. 2003;183:304-313. (Pubitemid 37243901)
12. Pulay AJ, Stinson FS, Ruan WJ, et al. The relationship of DSM-IV personality disorders to nicotine dependence-results from a national survey. Drug Alcohol Depend. 2010;108:141-145.
13. Rush B, Koegl CJ. Prevalence and profile of people with co-occurring mental and substance use disorders within a comprehensive mental health system. Can J Psychiatry. 2008;53:810-821.
14. Swendsen J, Conway KP, Degenhardt L, et al. Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. Addiction. 2010;105:1117-1128.
15. Sellman D. The 10 most important things known about addiction. Addiction. 2009;105:6-13.
16. Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess. 2006;10:1-165.
17. Frisher M, Crome I, Macleod J, et al. Substance misuse and psychiatric illness: prospective observational study using the general practice research database. J Epidemiol Community Health. 2005;59: 847-850. (Pubitemid 41360908)
18. Colpe LJ, Epstein JF, Barker PR, et al. Screening for serious mental illness in the National Survey on Drug Use and Health (NSDUH). Ann Epidemiol. 2009;19: 210-211.
19. Zimmerman M, Chelminski I, Young D, et al. Does DSM-IV capture the dimensional nature of personality disorders? J Clin Psychiatry. 2011;72: 1333-1339.
20. Insel TR, Wang PS. Rethinking mental illness. JAMA. 2010;303:1970-1971.
21. Cuthbert BN, Insel TH. Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria project. Schizophr Bull. 2010;36:1061-1062.
22. Fatséas M, Denis C, Lavie E, et al. Relationship between anxiety disorders and opiate dependence-a systematic review of the literature: implications for diagnosis and treatment. J Subst Abuse Treat. 2010;38:220-230.
23. Insel TR, Cuthbert BN. Endophenotypes: bridging genomic complexity and disorder heterogeneity. Biol Psychiatry. 2009;66:988-989.
24. Bava S, Tapert SF. Adolescent brain development and the risk for alcohol and other drug problems. Neuropsychol Rev. 2010;20:398-413.
25. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005;8:1445-1449. (Pubitemid 41573654)
26. Feltenstein MW, See RE. The neurocircuitry of addiction: an overview. Br J Pharmacol. 2008;154: 261-274. (Pubitemid 351670601)
27. Baker DA, McFarland K, Lake RW, et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci. 2003;6:743-749. (Pubitemid 36792890)
28. McClung CA, Ullery PG, Perroti LI, et al. FosB: a molecular switch for long term adaptation in the brain. Mol Brain Res. 2004;132:146-154. (Pubitemid 39586757)
29. Swendsen J, Le Moal M. Individual vulnerability to addiction. Ann NY Acad Sci. 2011;1216:73-85.
30. Goldman SM, Quinlan PJ, Ross W, et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol. 2012;71:776-784.
31. Thrash B, Thiruchelvan K, Ahuja M, et al. Methamphetamine-induced neurotoxicity: the road to Parkinson's disease. Pharmacol Rep. 2009;61:966-977.
32. Hart CL, Marvin CB, Silver R, et al. Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacology. 2012;37: 586-608.
33. Heilig M, Egli M, Crabbe JC, et al. Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol. 2010;15:169-184.
34. Bierut LJ. Genetic vulnerability and susceptibility to substance dependence. Neuron. 2011;69:618-627.
35. Terenius L, Johansson B. The opioid systems-panacea and nemesis. Biochem Biophys Res Commun. 2010;396:140-142.
36. Spreckelmeyer KN, PaulzenM, Raptis M, et al. Opiateinduced dopamine release is modulated by severity of alcohol dependence: an [(18)F] Fallypride Positron Emission Tomography study. Biol Psychiatry. 2011;70:770-776.
37. Prossin AR, Love TM, Koeppe RA, et al. Dysregulation of regional endogenous opioid function in borderline personality disorder. Am J Psychiatry. 2010; 167:925-933.
38. Stanley B, Sher L, Wilson S, et al. Non-suicidal selfinjurious behavior, endogenous opioids and monoamine neurotransmitters. J Affect Disord. 2010;124: 134-140.
39. Bandelow B, Schmahl C, Falkai P, et al. Borderline personality disorder: a dysregulation of the endogenous opioid system? Psychol Rev. 2010;117:623-636.
40. Sidhpura N, Parsons LH. Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. Neuropharmacology. 2011;61:1070-1087.
41. Hallak JE, Machado-de-Sousa JP, Crippa JA, et al. Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras Psiquiatr. 2010;32:56-61.
42. Müller-Vahl KR, Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother. 2008;8:1037-1048. (Pubitemid 351962072)
43. Freedman R. Cannabis, inhibitory neurons, and the progressive course of schizophrenia. Am J Psychiatry. 2008;165:416-419. (Pubitemid 351694281)
44. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008;192:306-307. (Pubitemid 351692406)
45. Allen MH, Debanné M, Lazignac C, et al. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2011; 168:395-399.
46. Andreasen JT, Redrobe JP, Nielsen EØ. Combined a7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987. Pharmacol Biochem Behav. 2012;100: 624-629.
47. Popoli M, Yan Z, McEwen BS, et al. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2011; 13:22-37.
48. Corominas M, Roncero C, Casas M. Corticotropin releasing factor and neuroplasticity in cocaine addiction. Life Sci. 2010;86:1-9.
49. Markou A. Metabotropic glutamate receptor antagonists: novel therapeutics for nicotine dependence and depression? Biol Psychiatry. 2007;61: 17-22. (Pubitemid 44855742)
50. Volkow ND, Wang GF, Fowler JS, et al. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci USA. 2011;108:15037-15042.
51. Kalivas PW, Volkow ND. New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol Psychiatry. 2011;16:974-986.
52. Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91-95.
53. Edwards S, Koob GF. Neurobiology of dysregulated motivational systems in drug addiction. Future Neurol. 2010;5:393-401.
54. Bush G. Cingulate, frontal, and parietal cortical dysfunction in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011;9:1160-1167.
55. Insel T. Is social attachment an addictive disorder? Physiol Behav. 2003;164:1637-1640.
56. Psychiatric GWAS Consortium Coordinating Committee. Genomewide Association Studies: History, rationale, and prospects for psychiatric disorders. Am J Psychiatry. 2009;166:540-556.
57. Welberg L. Addiction: from mechanisms to treatment. Nature Rev Neurosci. 2011;12:621.
58. Badiani A, Belin D, Epstein D, et al. Opiate versus psychostimulant addiction: the differences do matter. Nature Rev Neurosci. 2011;12:685-700.
59. Schuckit MA, Danko GP, Smith TL, et al. The prognostic implications of DSM-IV abuse criteria in drinking adolescents. Drug Alcohol Depend. 2008;97: 94-104.
60. Love TM, Stohler CS, Zubieta JK. Positron emission tomography measures of endogenous opioid neurotransmission and impulsiveness traits in humans. Arch Gen Psychiatry. 2009;66:1124-1134.
61. Volkow ND, Tomasi D, Wang GF, et al. Positive emotionality is associated with baseline metabolism in orbitofrontal cortex and in regions of the default network. Mol Psychiatry. 2011;16:818-825.
62. Aragay N, Roca A, Garcia B, et al. Pathological gambling in a psychiatric sample. Compr Psychiatry. 2012;53:9-14.
63. Grall-Bronnec M, Wainstein L, Augy J, et al. Attention deficit hyperactivity disorder among pathological and at-risk gamblers seeking treatment: a hidden disorder. Eur Addict Res. 2011;17:231-240.